 |
| Health News > FDA Approves Besivance to Treat Bacterial Conjunctivitis | 
|
ADVERTISEMENT | ADVERTISE WITH US
Health News Videos
The Importance of Monitoring Vitamin D Status in the U.S.
Dr. Howard Nash
The Importance of Monitoring Vitamin D Status in the U.S.
Dr. Howard Nash
The NIH Common Fund's Human Microbiome Project
Top News
Subscribe to this feed:
« Back
- The U.S. Food and Drug Administration approved Besivance (besifloxacin ophthalmic suspension 0.6 percent) for the treatment of bacterial conjunctivitis (non-viral), a contagious condition marked by irritation of the eyes and a discharge from the mucous membranes.
?Bacterial conjunctivitis is a common condition that affects people of all ages,? said Wiley A. Chambers, M.D., acting director of the Division of Anti-Infective and Ophthalmology Products in FDA?s Center for Drug Evaluation and Research. ?It is important to have a variety of treatment options available to health care professionals and patients because an effective drug therapy can reduce the duration of the illness and reduce the chances of infecting others.?Bacterial forms of conjunctivitis are common in childhood, but they can occur in people of any age.
Symptoms of bacterial conjunctivitis can include red eyes, swelling, eyelids sticking together, itching, watering and a white or yellow sticky discharge from the eyes. Bacterial conjunctivitis is generally a condition that runs its course in 7-14 days. Patients using the drug in clinical trials had a faster rate of resolution of the infection than those treated with a solution containing only a preservative. The drug was shown to be effective in treating patients age one year and older.
Adverse events were reported in less than 3 percent of patients in clinical trials.? Adverse reactions included redness of the eyes, blurred vision, eye pain, irritation and itching, and headache. Besivance is an eye drop for topical use on the eyes only. It should not be injected into the eye. Besivance is made by Bausch & Lomb, Rochester, N.Y.
FDA Approves Besivance to Treat Bacterial Conjunctivitis
| May 28th 2009 | Diseases Vision |
- The U.S. Food and Drug Administration approved Besivance (besifloxacin ophthalmic suspension 0.6 percent) for the treatment of bacterial conjunctivitis (non-viral), a contagious condition marked by irritation of the eyes and a discharge from the mucous membranes.
?Bacterial conjunctivitis is a common condition that affects people of all ages,? said Wiley A. Chambers, M.D., acting director of the Division of Anti-Infective and Ophthalmology Products in FDA?s Center for Drug Evaluation and Research. ?It is important to have a variety of treatment options available to health care professionals and patients because an effective drug therapy can reduce the duration of the illness and reduce the chances of infecting others.?Bacterial forms of conjunctivitis are common in childhood, but they can occur in people of any age.
Symptoms of bacterial conjunctivitis can include red eyes, swelling, eyelids sticking together, itching, watering and a white or yellow sticky discharge from the eyes. Bacterial conjunctivitis is generally a condition that runs its course in 7-14 days. Patients using the drug in clinical trials had a faster rate of resolution of the infection than those treated with a solution containing only a preservative. The drug was shown to be effective in treating patients age one year and older.
Adverse events were reported in less than 3 percent of patients in clinical trials.? Adverse reactions included redness of the eyes, blurred vision, eye pain, irritation and itching, and headache. Besivance is an eye drop for topical use on the eyes only. It should not be injected into the eye. Besivance is made by Bausch & Lomb, Rochester, N.Y.
Related articles
- Higher Oxygen Levels Improve Preterm Survival, Increase Risk for Eye Condition
- Additional Genes Associated with Age-Related Macular Degeneration Identified
- New Treatment Found to Reduce Vision Loss from Central Retinal Vein Occlusion
- Gene Therapy One Year Later: Patients Healthy and Maintain Early Visual Improvement
Add your own comments
Comments:
No commentsHealth Resource Centers
|
Copyright 2009-2010 Emma Concepts, Inc. All rights reserved. |
About us & FAQ |
Terms of Service |
Privacy Policy |
Advertise
Healthimize.com’s content is for educational purposes only and this page and other pages on Healthimize do not contain medical advice. The information on this website is not a substitute for professional medical advice. Users further agree to abide by the terms of service. Trademarks are properties of their respective owners. |